Morgan Stanley analyst Tejas Savant raised the firm’s price target on Veracyte (VCYT) to $40 from $28 and keeps an Underweight rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- NCCN guidelines incrementally favorable for Veracyte’s Decipher, says Guggenheim
- Veracyte Inc. Reports Robust Q3 Earnings Performance
- Veracyte rises 21.4%
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- Veracyte rises 26.4%